Beverly Hospital

Futó vizsgálatok

• Fut, nem toboroz

  Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer

  NCT06732401· 3. fázis· Forrás

• Toboroz

  Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

  NCT06616584· 2/3. fázis· Forrás

• Toboroz

  Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

  NCT06498635· 3. fázis· Forrás

• Toboroz

  Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

  NCT06661720· 3. fázis· Forrás

• Fut, nem toboroz

  Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

  NCT06632327· 3. fázis· Forrás

• Toboroz

  Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

  NCT06116682· 2. fázis· Forrás

• Toboroz

  Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer

  NCT06205485· 3. fázis· Forrás

• Toboroz

  Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

  NCT05987241· 2/3. fázis· Forrás

• Toboroz

  Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

  NCT05879926· 3. fázis· Forrás

• Toboroz

  Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

  NCT05929768· 3. fázis· Forrás

• Fut, nem toboroz

  Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

  NCT05633602· 3. fázis· Forrás

• Toboroz

  Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

  NCT05327686· 2. fázis· Forrás

• Toboroz

  Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

  NCT05174169· 2/3. fázis· Forrás

• Fut, nem toboroz

  Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

  NCT05096663· 2/3. fázis· Forrás

• Fut, nem toboroz

  Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

  NCT05050084· 3. fázis· Forrás

• Fut, nem toboroz

  Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

  NCT04625647· 2. fázis· Forrás

• Fut, nem toboroz

  Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study

  NCT04484818· 3. fázis· Forrás

• Fut, nem toboroz

  Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients

  NCT04310020· 2. fázis· Forrás

• Toboroz

  Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

  NCT04181060· 3. fázis· Forrás

• Fut, nem toboroz

  Making Informed Choices on Incorporating Chemoprevention Into Care (MiCHOICE)

  NCT04496739· Forrás

• Fut, nem toboroz

  Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer

  NCT04214262· 3. fázis· Forrás

• Fut, nem toboroz

  Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker

  NCT04334941· 2. fázis· Forrás

• Toboroz

  Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

  NCT04267848· 3. fázis· Forrás

• Fut, nem toboroz

  NCI COVID-19 in Cancer Patients, NCCAPS Study

  NCT04387656· Forrás

• Fut, nem toboroz

  Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

  NCT04092283· 3. fázis· Forrás

• Fut, nem toboroz

  Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer

  NCT03793179· 3. fázis· Forrás

• Toboroz

  Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

  NCT03851445· 2/3. fázis· Forrás

• Fut, nem toboroz

  Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

  NCT03660826· 2. fázis· Forrás

• Fut, nem toboroz

  Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

  NCT03055013· 3. fázis· Forrás

• Fut, nem toboroz

  Breast Cancer WEight Loss Study (BWEL Study)

  NCT02750826· 3. fázis· Forrás

• Fut, nem toboroz

  Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)

  NCT02595944· 3. fázis· Forrás

• Fut, nem toboroz

  Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

  NCT02785952· 3. fázis· Forrás

• Fut, nem toboroz

  Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

  NCT02506153· 3. fázis· Forrás

• Fut, nem toboroz

  Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

  NCT02445391· 3. fázis· Forrás

• Fut, nem toboroz

  Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

  NCT02465060· 2. fázis· Forrás

• Fut, nem toboroz

  Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

  NCT02488967· 3. fázis· Forrás

• Fut, nem toboroz

  Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

  NCT02201992· 3. fázis· Forrás

• Fut, nem toboroz

  Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

  NCT02193282· 3. fázis· Forrás

• Fut, nem toboroz

  Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

  NCT02194738· Forrás

• Fut, nem toboroz

  Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

  NCT02115282· 3. fázis· Forrás

• Fut, nem toboroz

  Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  NCT02048813· 3. fázis· Forrás

• Fut, nem toboroz

  Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

  NCT01886872· 3. fázis· Forrás

• Fut, nem toboroz

  S0820, Adenoma and Second Primary Prevention Trial

  NCT01349881· 3. fázis· Forrás

• Fut, nem toboroz

  Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

  NCT01169337· 3. fázis· Forrás

• Fut, nem toboroz

  Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

  NCT00588770· 3. fázis· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Tüdőrák5 toboroz
• Vastagbélrák2 toboroz
• Hólyagrák1 toboroz
• Petefészekrák1 toboroz
• Tripla negatív emlőrák1 toboroz
• Vesedaganat1 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Lezárult

  Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

  NCT03971474· 2. fázis· Forrás

• Lezárult

  Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

  NCT03845296· 2. fázis· Forrás

• Leállították

  Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

  NCT03199885· 3. fázis· Forrás

• Lezárult

  Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer

  NCT03382561· 2. fázis· Forrás

• Lezárult

  S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

  NCT03365882· 2. fázis· Forrás

• Lezárult

  S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer

  NCT02438722· 2/3. fázis· Forrás

• Lezárult

  S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

  NCT01120249· 3. fázis· Forrás

• Lezárult

  Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery

  NCT00324805· 3. fázis· Forrás